The AVAT No-Fault Compensation Program for Participating Member States (the “Program”) provides no-fault lump-sum compensation in full and final settlement of any claims to individuals who have suffered a Serious Adverse Event resulting in permanent Impairment or death associated with a COVID-19 vaccine procured or distributed under the AVAT Framework, or the administration of such a Vaccine, within any of the Participating Member States.
A number of conditions need to be met:
- for an Application to be eligible for consideration and;
- if an Application is eligible for consideration, in order for you (or the person you represent) to be eligible to receive compensation under the Program.
These conditions are described in the Program Protocol.
The Program is administered by ESIS, Inc., as the Program’s independent claims administrator (the “Administrator”). ESIS has over 30 years of relevant claims handling experience and has secured Contact Centers in Africa and the Caribbean to be able to assist Program applicants in all Participating Member States.
The Administrator does not charge any fee to download or submit any Program forms. Exercise extreme caution in respect of any emails, text messages, telephone calls or other communications requesting you to make a payment as a condition for downloading or submitting an Application Form or any other forms under the Program.
Do not make any such payment under any circumstances, as such emails, text messages, telephone calls or other communications are fraudulent and do not originate from the Administrator.
What the Program Does Not Cover
- Any non-Serious Adverse Events associated with any COVID-19 Vaccine received through the AVAT Framework in any of the Participating Member States; or
- Any adverse events (whether serious or non-serious) arising from any COVID-19 vaccine that:
- Has not been received through the AVAT Framework; or
- Has been administered in any country or territory that is not a Participating Member State; or
- Any Serious Adverse Events arising from a COVID-19 Vaccine received through the AVAT Framework in any Participating Member State, if the vaccine is administered after the Vaccine’s Scope of Coverage End Point (after more than two years from date the Vaccine was first marketed in any Participating Member State under the AVAT Framework). See Schedule 1 (List of Vaccines) to the Program Protocol, for this date); or
- Any Serious Adverse Events arising from a COVID-19 vaccine received through the AVAT Framework in any Participating Member State for which an application is submitted to the Administrator after the end of the Reporting Period. For more information about the Reporting Period, please see Schedule 7 (Illustrative Diagram of the Reporting Period) and the Frequently Asked Questions.
The African Vaccine Acquisition Trust of 7th Floor, Happy World House, 37 Sir William Newton Street, Port-Louis 11328, Mauritius, a centralised negotiating, purchasing, and payment agent incorporated on behalf of the AU Member States and CARICOM Member States for the purchase of COVID-19 vaccines pursuant to the AVAT Framework.
The AVAT No Fault Compensation Scheme, as detailed in the Protocol and its Schedules.
Any AU Member State or CARICOM State that has elected to participate in the AVAT No Fault Compensation Scheme and “Participating Member States” shall mean all such states that have elected to participate in the AVAT No Fault Compensation Scheme.
A serious untoward medical occurrence that (i) is sustained or suffered by a Patient following the administration of a Vaccine, and (ii) results in an Injury, as defined in the Program's Protocol.
A significant deviation, loss, or loss of use of any body structure or body function in an individual with a health condition, disorder, or disease.
The evaluation of an Impairment as provided in the Program's Protocol will be based upon the most recently published edition of the American Medical Association’s Guides to the Evaluation of Permanent Impairment (AMA’s Guides). Impairment percentages or ratings contained in the AMA’s Guides have been developed by medical specialists and are consensus-derived estimates that reflect the severity of the medical condition and the degree to which the Impairment decreases an individual’s ability to perform common activities of daily living.
The Impairment rating is a percentage that represents the extent of a whole person impairment of an individual, based on the organ or body function affected by an Injury (as defined in the Program's Protocol).
A mechanism structured by AVATT in collaboration with the African Export-Import Bank to establish a pan-African centralized procurement platform to ensure Africa’s access to COVID-19 vaccines by creating AVAT and providing assurance for the payment to identified vaccine manufacturers.
A COVID-19 vaccine received in any Participating Member State through the AVAT Framework that:
- either (A) has licensure or authorization from a stringent (“functional”) regulatory authority or (B) has received WHO prequalification, following licensure or authorization from a stringent (“functional”) regulatory authority, or (C) has been issued authorization for emergency use based on licensure or authorization by a stringent (“functional”) regulatory authority; and
- is included in Schedule 1 to the Program's Protocol, as updated from time to time; and
- has received all required approvals and authorizations for importation, distribution, and use in the relevant Participating Member State; and
- has not reached its Scope of Coverage Endpoint.
A written claim for compensation completed by an Applicant on the application form approved by and provided by the Administrator, as set forth in Schedule 2 to the Program's Protocol, which must be accompanied by all Supporting Evidence, using the prescribed form in Schedule 3 to the Program’s Protocol.
ESIS, Inc., the claims Administrator appointed to manage and administer the Program, including, but not limited to, the receipt and registration of Applications, distributing acknowledgements of receipt of Applications, setting financial reserves for Receivable Claims, review of Applications, Supporting Evidence, and other documents to assess receivability, assessing Receivable Claims, and approve or deny, as the case may be, Payment for compensation, in accordance with the terms of the Program's Protocol.
for each Vaccine, the date which is 24 months following the date on which a Vaccine was first put into circulation by the relevant Vaccine manufacturer within the AVAT Framework following regulatory approval or an emergency use authorization of such Vaccine by any regulator.
On a per Vaccine basis, the period during which an Applicant may file an Application for compensation under the Program in respect of such Vaccine. The maximum Reporting Period for each Vaccine extends from:
- the date on which such Vaccine was first put into circulation by the manufacturer within the AVAT Framework, following regulatory approval or an emergency use authorization of such Vaccine by any regulator (as indicated in Schedule 1 to the Program's Protocol); and
- terminates on the date which is 36 calendar months immediately after the Scope of Coverage Endpoint for such Vaccine (as indicated in Schedule 1 to the Program's Protocol), provided always that the Vaccine was administered before this Vaccine’s Scope of Coverage Endpoint (as defined in Section 2 of the Program's Protocol and indicated in Schedule 1 to the Program's Protocol). See the illustrative diagram of the Reporting Period attached as Schedule 7 to the Program's Protocol. For each Patient, the Reporting Period depends on the date the Vaccine was administered to the Patient. To calculate the Reporting Period that applies to the Patient, the Patient (or a person who is a duly authorized to represent the Patient as provided in part (ii) of the definition of Applicant in the Program's Protocol) needs to:
- determine (through Schedule 1 to the Program's Protocol) what is the date of the Scope of Coverage End Point that applies to the Vaccine that was administered to Patient; and
- calculate the number of months and days from the vaccination date (i.e. date that the Vaccine was administered to the Patient) until the date of the Vaccine’s Scope of Coverage End Point, and add another 36 months. This establishes the Reporting Period that applies to the Patient.